vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Cable One, Inc. (CABO). Click either name above to swap in a different company.
Cable One, Inc. is the larger business by last-quarter revenue ($363.7M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -6.1%). Cable One, Inc. produced more free cash flow last quarter ($71.6M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -5.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Cable One, Inc. is an American broadband communications provider. Under the Sparklight brand, it provides cable television, internet, and phone services to 24 U.S. states and 1.1 million residential and business customers. It also owns the Fidelity Communications brand, which provides the same services in Arkansas, Louisiana, Missouri, Oklahoma, and Texas. Fidelity was founded in 1940. It is headquartered in Phoenix, Arizona, though it does not serve that metro area.
ANIP vs CABO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $363.7M |
| Net Profit | $27.5M | — |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 25.2% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | -6.1% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $363.7M | ||
| Q3 25 | $227.8M | $376.0M | ||
| Q2 25 | $211.4M | $381.1M | ||
| Q1 25 | $197.1M | $380.6M | ||
| Q4 24 | $190.6M | $387.2M | ||
| Q3 24 | $148.3M | $393.6M | ||
| Q2 24 | $138.0M | $394.5M | ||
| Q1 24 | $137.4M | $404.3M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $86.5M | ||
| Q2 25 | $8.5M | $-438.0M | ||
| Q1 25 | $15.7M | $2.6M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $44.2M | ||
| Q2 24 | $-2.3M | $38.2M | ||
| Q1 24 | $18.2M | $37.4M |
| Q4 25 | 14.1% | 25.2% | ||
| Q3 25 | 15.9% | 25.2% | ||
| Q2 25 | 6.6% | -128.4% | ||
| Q1 25 | 13.3% | 25.1% | ||
| Q4 24 | -2.3% | 26.2% | ||
| Q3 24 | -13.8% | 28.0% | ||
| Q2 24 | 3.7% | 27.9% | ||
| Q1 24 | 14.8% | 29.6% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 23.0% | ||
| Q2 25 | 4.0% | -114.9% | ||
| Q1 25 | 8.0% | 0.7% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 11.2% | ||
| Q2 24 | -1.7% | 9.7% | ||
| Q1 24 | 13.2% | 9.2% |
| Q4 25 | $1.14 | $-0.49 | ||
| Q3 25 | $1.13 | $14.52 | ||
| Q2 25 | $0.36 | $-77.70 | ||
| Q1 25 | $0.69 | $0.46 | ||
| Q4 24 | $-0.45 | $-18.05 | ||
| Q3 24 | $-1.27 | $7.58 | ||
| Q2 24 | $-0.14 | $6.58 | ||
| Q1 24 | $0.82 | $6.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $152.8M |
| Total DebtLower is stronger | — | $2.6B |
| Stockholders' EquityBook value | $540.7M | $1.4B |
| Total Assets | $1.4B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $152.8M | ||
| Q3 25 | $262.6M | $166.6M | ||
| Q2 25 | $217.8M | $152.9M | ||
| Q1 25 | $149.8M | $149.1M | ||
| Q4 24 | $144.9M | $153.6M | ||
| Q3 24 | $145.0M | $226.6M | ||
| Q2 24 | $240.1M | $201.5M | ||
| Q1 24 | $228.6M | $210.7M |
| Q4 25 | — | $2.6B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.6B | ||
| Q3 24 | — | $3.5B | ||
| Q2 24 | — | $3.5B | ||
| Q1 24 | — | $3.6B |
| Q4 25 | $540.7M | $1.4B | ||
| Q3 25 | $505.8M | $1.4B | ||
| Q2 25 | $436.8M | $1.3B | ||
| Q1 25 | $418.6M | $1.8B | ||
| Q4 24 | $403.7M | $1.8B | ||
| Q3 24 | $405.9M | $1.9B | ||
| Q2 24 | $455.8M | $1.9B | ||
| Q1 24 | $452.0M | $1.9B |
| Q4 25 | $1.4B | $5.6B | ||
| Q3 25 | $1.4B | $5.7B | ||
| Q2 25 | $1.3B | $5.8B | ||
| Q1 25 | $1.3B | $6.4B | ||
| Q4 24 | $1.3B | $6.5B | ||
| Q3 24 | $1.3B | $6.7B | ||
| Q2 24 | $920.8M | $6.7B | ||
| Q1 24 | $914.5M | $6.7B |
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 1.88× | ||
| Q2 25 | — | 2.16× | ||
| Q1 25 | — | 1.66× | ||
| Q4 24 | — | 1.99× | ||
| Q3 24 | — | 1.84× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 1.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $145.5M |
| Free Cash FlowOCF − Capex | $29.1M | $71.6M |
| FCF MarginFCF / Revenue | 11.8% | 19.7% |
| Capex IntensityCapex / Revenue | 0.5% | 20.3% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $278.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $145.5M | ||
| Q3 25 | $44.1M | $156.5M | ||
| Q2 25 | $75.8M | $144.9M | ||
| Q1 25 | $35.0M | $116.3M | ||
| Q4 24 | $15.9M | $167.6M | ||
| Q3 24 | $12.5M | $176.2M | ||
| Q2 24 | $17.4M | $155.5M | ||
| Q1 24 | $18.3M | $164.8M |
| Q4 25 | $29.1M | $71.6M | ||
| Q3 25 | $38.0M | $84.8M | ||
| Q2 25 | $71.8M | $76.6M | ||
| Q1 25 | $32.5M | $45.2M | ||
| Q4 24 | $13.5M | $95.7M | ||
| Q3 24 | $7.7M | $99.2M | ||
| Q2 24 | $13.0M | $84.0M | ||
| Q1 24 | $13.7M | $98.9M |
| Q4 25 | 11.8% | 19.7% | ||
| Q3 25 | 16.7% | 22.5% | ||
| Q2 25 | 34.0% | 20.1% | ||
| Q1 25 | 16.5% | 11.9% | ||
| Q4 24 | 7.1% | 24.7% | ||
| Q3 24 | 5.2% | 25.2% | ||
| Q2 24 | 9.4% | 21.3% | ||
| Q1 24 | 10.0% | 24.5% |
| Q4 25 | 0.5% | 20.3% | ||
| Q3 25 | 2.7% | 19.1% | ||
| Q2 25 | 1.9% | 17.9% | ||
| Q1 25 | 1.3% | 18.7% | ||
| Q4 24 | 1.3% | 18.6% | ||
| Q3 24 | 3.2% | 19.6% | ||
| Q2 24 | 3.2% | 18.1% | ||
| Q1 24 | 3.3% | 16.3% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 1.81× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 44.62× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.99× | ||
| Q2 24 | — | 4.08× | ||
| Q1 24 | 1.00× | 4.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CABO
Segment breakdown not available.
